Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%

Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution

48 projects approved under PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs

The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs

Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India

Godavari Biorefineries secures Chinese patent for anti-cancer molecule

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook

Sarepta refuses to comply with FDA request to stop shipping gene therapy Elevidys

FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D

ImCheck’s ICT01 receives FDA ODD for treatment of acute myeloid leukemia

Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials

Kenvue collaborates with API to launch India’s first cough clinics

Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty